A Season of Change: Why the REMS Industry Consortium Matters More Than Ever

In a time where Zoom and Teams virtual meetings have become the daily norm, there is still something uniquely powerful about face-to-face conversation. That is what made the REMS Industry Consortium (RIC) Annual Meeting in March more than just another event, providing an ideal opportunity to connect, collaborate, and communicate in ways that no virtual meeting can match.

There is a certain energy that comes from being in the same room. Conversations flow more naturally, ideas spark more freely, and trust is built in real time. The in-person experience opens the door for deeper discussions, spontaneous brainstorming, and the kind of nuance that gets lost in a digital grid of faces. With REMS (Risk Evaluation and Mitigation Strategies) specifically, that kind of interaction is not just valuable, it is essential.

And, the timing could not have been more relevant!

There is a season of change upon us, where the pharmaceutical and biotechnology industries and federal agencies are facing accelerated shifts. Some are clearly on the horizon; others are still taking shape. Whether it is new policy directions, leadership updates, or evolving regulatory expectations, there is a shared sense that we are at a turning point.

The Annual RIC Meeting provided a unique opportunity to come together as one comprehensive team. Across companies, roles, and sectors, those who attended had the chance to ask REMS questions, share concerns, and build a collective understanding of what is ahead.

In these uncertain times, that kind of unity can make all the difference. 

RIC leadership successfully designed the meeting to be both fruitful and constructive. From opening remarks with key representatives to REMS breakout sessions, the two-day meeting was packed with discussions focused on the issues at hand. Insight from partners on leveraging AI to advance REMS efforts was informative, the Sponsor-led session on incorporating stakeholder feedback was particularly insightful, and MMS CEO, Dr. Uma Sharma spoke on the effects on changing regulations and their impact on the industry.

An Ongoing REMS Evolution

What is particularly important now is recognizing that these changes will continue; they are part of an ongoing REMS evolution. Many federal agencies are experiencing a dynamic mix of upheaval and growth. That means our strategies, conversations, and collaborations need to be just as agile.

Among the shifts is how the US Food & Drug Administration (FDA) is approaching REMS. Signals are clear: the data we gather through REMS is not just another regulatory checkbox. It is becoming a vital part of how decisions are made, whether to release, expand, or initiate new REMS programs.

In this context, the Annual RIC Meeting became a compass for the industry, providing a chance to align, prepare, and move forward together as the landscape continues to evolve.  As an industry partner to the RIC, MMS understands the critical need for collaboration.

A Playbook for Understanding REMS Better

To that end, MMS released a must-read resource for those navigating the complexities of REMS requirements: the REMS Playbook. Designed to help Sponsors build, refine, or reimagine their REMS strategies, the playbook breaks down the FDA’s six determining factors for REMS programs and outlines the five essential components every REMS should include.

Helping to prepare for submission or optimizing an existing program, the playbook offers clear, practical insights rooted in regulatory expertise. If you missed the event, you can still download it now to gain a stronger, more strategic foundation for your REMS planning.

To ask a REMS expert your specific questions, email info@mmsholdings.com and we’ll connect you with the right person to help ensure a safe, efficient path to market for your drug.